2018

1. Balixafortide (a novel CXCR4 inhibitor) and eribulin in HER2-neg metastatic breast cancer (MBC) patients (pts): A phase I trial

   Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii91-viii92

2. Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial

   The Lancet Oncology, Vol. 19, Núm. 6, pp. 812-824